S1156
Clinical - Urology
ESTRO 2026
information. Keywords: Prostate cancer, triptorelin, quality of life
14.50 ng/ml [7.30,34.33] at baseline and 0.25 [0.05,1.20] at 6mFU. Baseline and 6mFU scores of QLQ-PR25 domains, and their changes from baseline to 6mFU, are presented in Table 2. Mean (sd) scores changes were, respectively, 8.37 (15.97) for HTRS and - 8.22 (22.26) for SA subscales, meaning there was a small (< 10 points) deterioration of both subscales. Mean scores changes of urinary and bowel symptoms subscales were almost null, and changes of incontinence aid and sexual functioning had too many missing data to draw conclusions. From multivariate analyses, factors linked with deterioration of HTRS (higher scores) were presence of comorbidity, metastatic stage, prescription of the 6-month formulation; those linked with improvement were worse baseline score, older age, anti-androgen concomitant treatment. Factors linked with deterioration of SA (lower scores) were higher baseline score, older age; while prescription of the 6-month formulation was linked with improvement. Data collected across these studies showed no new or unexpected safety concerns.
Digital Poster 904 Moderate vs. Ultrahypofractionated Curative Radiotherapy for De Novo Very High-Risk Oligometastatic Prostate Cancer: A Retrospective Comparison Angel Montero, Mercedes Lopez, Ovidio Hernando, Jeannette Valero, Emilio Sanchez, Xin Chen-Zhao, Raquel Ciervide, Beatriz Alvarez, Bruno Zambrana, Raquel Sanchez, Mariola Garcia-Aranda, Rosa Alonso, Carmen Rubio Radiation Oncology, HM Hospitales, Madrid, Spain Purpose/Objective: To compare outcomes and toxicity of two curative- intent radiotherapy schedules in de novo very high- risk oligometastatic prostate cancer: moderate
hypofractionation (MHF, 21 × 3 Gy) versus ultrahypofractionation (UHF, 5 × 8 Gy). Material/Methods:
Forty-four men with prostate adenocarcinoma and synchronous locoregional and/or ≤ 5 bone metastases were analyzed; visceral disease was excluded. Between 2015–2020, 26 patients received MHF; between 2020–2025, 18 received UHF.In the MHF group, median age was 69.5 y (52–84) and follow-up 15.5 m (3–65). Mean/median PSA were 32.5/113 ng/mL (2.6–295). Metastases were nodal (69%), bone (15.5%), or simultaneous bone and nodal (15.5%). In the UHF group, median age was 73.5 y (52–84) and follow-up 14.5 m (1–39). Mean/median PSA were 37.5/27.25 ng/mL (5.81–146); 61% had nodal, 22% bone, and 17% simultaneous bone and nodal metastases.All patients received androgen deprivation with antiandrogens and GnRH analogues. In MHF, two patients completed six cycles of docetaxel and three received abiraterone + prednisone for 12–22 months; in UHF, four received abiraterone + prednisone for 24 months.Complete characteristics of both cohorts are detailed in Table 1.
Conclusion: This pooled analysis of a high number of patients provided several data in the real life setting. Deteriorations of HRQoL subscales (HTRS and SA) were aligned with ADT literature, as were the conclusions on the other subscales. In this large population, subgroups with higher deterioration could be identified. It may allow anticipation with a personalized medical approach and enhanced
Made with FlippingBook - Share PDF online